149 related articles for article (PubMed ID: 20979931)
1. Associations between oxaliplatin-induced peripheral neuropathy and polymorphisms of the ERCC1 and GSTP1 genes.
Inada M; Sato M; Morita S; Kitagawa K; Kawada K; Mitsuma A; Sawaki M; Fujita K; Ando Y
Int J Clin Pharmacol Ther; 2010 Nov; 48(11):729-34. PubMed ID: 20979931
[TBL] [Abstract][Full Text] [Related]
2. Associations between glutathione S-transferase pi Ile105Val and glyoxylate aminotransferase Pro11Leu and Ile340Met polymorphisms and early-onset oxaliplatin-induced neuropathy.
Kanai M; Yoshioka A; Tanaka S; Nagayama S; Matsumoto S; Nishimura T; Niimi M; Teramukai S; Takahashi R; Mori Y; Kitano T; Ishiguro H; Yanagihara K; Chiba T; Fukushima M; Matsuda F
Cancer Epidemiol; 2010 Apr; 34(2):189-93. PubMed ID: 20308030
[TBL] [Abstract][Full Text] [Related]
3. GSTP1, ERCC1 and ERCC2 polymorphisms, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in colorectal cancer in Chinese population.
Li HY; Ge X; Huang GM; Li KY; Zhao JQ; Yu XM; Bi WS; Wang YL
Asian Pac J Cancer Prev; 2012; 13(7):3465-9. PubMed ID: 22994779
[TBL] [Abstract][Full Text] [Related]
4. Genetic polymorphisms associated with oxaliplatin-induced peripheral neurotoxicity in Japanese patients with colorectal cancer.
Oguri T; Mitsuma A; Inada-Inoue M; Morita S; Shibata T; Shimokata T; Sugishita M; Nakayama G; Uehara K; Hasegawa Y; Ando Y
Int J Clin Pharmacol Ther; 2013 Jun; 51(6):475-81. PubMed ID: 23547850
[TBL] [Abstract][Full Text] [Related]
5. [Association between genetic polymorphisms of ERCC1, XRCC1, GSTP1 and survival of advanced gastric cancer patients treated with oxaliplatin/5-Fu-based chemotherapy].
Liang J; Li QF; Yao RY; Lü HY; Jiang J; Sun YY; Song SA; Jiang T
Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):515-9. PubMed ID: 21029695
[TBL] [Abstract][Full Text] [Related]
6. Genetic polymorphisms of GSTP1 related to response to 5-FU-oxaliplatin-based chemotherapy and clinical outcome in advanced colorectal cancer patients.
Jun L; Haiping Z; Beibei Y
Swiss Med Wkly; 2009 Dec; 139(49-50):724-8. PubMed ID: 20047135
[TBL] [Abstract][Full Text] [Related]
7. A phase II clinical study of mFOLFOX6 plus bevacizumab as first-line therapy for Japanese advanced/recurrent colorectal cancer patients.
Nishina T; Takano Y; Denda T; Yasui H; Takeda K; Ura T; Esaki T; Okuyama Y; Kondo K; Takahashi Y; Sugiyama Y; Muro K
Jpn J Clin Oncol; 2013 Nov; 43(11):1080-6. PubMed ID: 23999770
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy.
Ruzzo A; Graziano F; Loupakis F; Rulli E; Canestrari E; Santini D; Catalano V; Ficarelli R; Maltese P; Bisonni R; Masi G; Schiavon G; Giordani P; Giustini L; Falcone A; Tonini G; Silva R; Mattioli R; Floriani I; Magnani M
J Clin Oncol; 2007 Apr; 25(10):1247-54. PubMed ID: 17401013
[TBL] [Abstract][Full Text] [Related]
9. Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy.
Lecomte T; Landi B; Beaune P; Laurent-Puig P; Loriot MA
Clin Cancer Res; 2006 May; 12(10):3050-6. PubMed ID: 16707601
[TBL] [Abstract][Full Text] [Related]
10. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer.
Stoehlmacher J; Park DJ; Zhang W; Yang D; Groshen S; Zahedy S; Lenz HJ
Br J Cancer; 2004 Jul; 91(2):344-54. PubMed ID: 15213713
[TBL] [Abstract][Full Text] [Related]
11. Influence of GSTP1 I105V polymorphism on cumulative neuropathy and outcome of FOLFOX-4 treatment in Asian patients with colorectal carcinoma.
Chen YC; Tzeng CH; Chen PM; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Wang WS
Cancer Sci; 2010 Feb; 101(2):530-5. PubMed ID: 19922504
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetics of oxaliplatin as adjuvant treatment in colon carcinoma: are single nucleotide polymorphisms in GSTP1, ERCC1, and ERCC2 good predictive markers?
Fariña Sarasqueta A; van Lijnschoten G; Lemmens VE; Rutten HJ; van den Brule AJ
Mol Diagn Ther; 2011 Oct; 15(5):277-83. PubMed ID: 21958378
[TBL] [Abstract][Full Text] [Related]
13. Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients.
Kweekel DM; Gelderblom H; Antonini NF; Van der Straaten T; Nortier JW; Punt CJ; Guchelaar HJ
Eur J Cancer; 2009 Mar; 45(4):572-8. PubMed ID: 19084393
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer.
Kwon HC; Roh MS; Oh SY; Kim SH; Kim MC; Kim JS; Kim HJ
Ann Oncol; 2007 Mar; 18(3):504-9. PubMed ID: 17322540
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetic and ethnicity influence on oxaliplatin therapy for colorectal cancer: a meta-analysis.
Shahnam A; Ridha Z; Wiese MD; Kichenadasse G; Sorich MJ
Pharmacogenomics; 2016 Oct; 17(15):1725-1732. PubMed ID: 27636246
[TBL] [Abstract][Full Text] [Related]
16. Influences of ERCC1, ERCC2, XRCC1, GSTP1, GSTT1, and MTHFR polymorphisms on clinical outcomes in gastric cancer patients treated with EOF chemotherapy.
Liu R; Zhao X; Liu X; Chen Z; Qiu L; Geng R; Guo W; He G; Yin J; Li J; Zhu X
Tumour Biol; 2016 Feb; 37(2):1753-62. PubMed ID: 26314858
[TBL] [Abstract][Full Text] [Related]
17. Polymorphisms in p53, GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy.
Huang ZH; Hua D; Du X
Cancer Chemother Pharmacol; 2009 Oct; 64(5):1001-7. PubMed ID: 19247656
[TBL] [Abstract][Full Text] [Related]
18. Effect of DPYD, MTHFR, ABCB1, XRCC1, ERCC1 and GSTP1 on chemotherapy related toxicity in colorectal carcinoma.
Puerta-García E; Urbano-Pérez D; Carrasco-Campos MI; Pérez-Ramírez C; Segura-Pérez A; Calleja-Hernández ; Cañadas-Garre M
Surg Oncol; 2020 Dec; 35():388-398. PubMed ID: 33035787
[TBL] [Abstract][Full Text] [Related]
19. Large-scale prospective pharmacogenomics study of oxaliplatin-induced neuropathy in colon cancer patients enrolled in the JFMC41-1001-C2 (JOIN Trial).
Kanai M; Kawaguchi T; Kotaka M; Shinozaki K; Touyama T; Manaka D; Ishigure K; Hasegawa J; Munemoto Y; Matsui T; Takagane A; Ishikawa H; Matsumoto S; Sakamoto J; Saji S; Yoshino T; Ohtsu A; Watanabe T; Matsuda F
Ann Oncol; 2016 Jun; 27(6):1143-1148. PubMed ID: 27069012
[TBL] [Abstract][Full Text] [Related]
20. ERCC1 and XPD/ERCC2 polymorphisms' predictive value of oxaliplatin-based chemotherapies in advanced colorectal cancer has an ethnic discrepancy: a meta-analysis.
Lu X; Xiao S; Jin C; van der Straaten T; Li X
J Clin Lab Anal; 2012 Jan; 26(1):10-5. PubMed ID: 24833529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
